Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instea...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Davies, C, Pan, H, Gray, R, Collins, R, Delmestri, A, Wang, Y, Peto, R, Godwin, J, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Khaled, H, Bonfill, X, Tort, S, Urrútia, G, Bradbury, J, Davis, SR, Clarke, M, Forbes, J, Haddad, P, Hou, M, Inbar, M, Kielanowska, J
Médium:	Journal article
Vydáno:	2013

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Autor Davies, C, Pan, H, Godwin, J, Gray, R, Arriagada, R, Raina, V, Abraham, M, Medeiros Alencar, V, Badran, A, Bonfill, X, Bradbury, J, Clarke, M, Collins, R, Davis, SR, Delmestri, A, Forbes, J, Haddad, P, Hou, M, Inbar, M, Khaled, H, Kielanowska, J, Kwan, W, Mathew, B, Mittra, I, Müller, B

Vydáno 2013

Journal article

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Podobné jednotky